Drugs / Dabogratinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07265947 | Dec 2025 → Oct 2030 expected | renal pelvis/ureter urothelial carcinoma | Tyra Biosciences, Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-09-09 | Tyra Biosciences, Inc | Results Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib tyra.bio ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-09 | Tyra Biosciences, Inc | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib tyra.bio ↗ |
| 2026-09-04 | Tyra Biosciences, Inc | Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 tyra.bio ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dabogratinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07265947 ↗ |
| Route | Oral | “Oral tablet(s) given daily” NCT07265947 ↗ |